Comparative effects of dexmedetomidine and propofol on brain and lung damage in experimental acute ischemic stroke.
Animals
Brain
/ drug effects
Brain Ischemia
/ prevention & control
Dexmedetomidine
/ administration & dosage
Disease Models, Animal
Endothelial Cells
/ drug effects
Hypnotics and Sedatives
/ administration & dosage
Interleukin-1beta
/ biosynthesis
Interleukin-6
/ biosynthesis
Ischemic Stroke
/ drug therapy
Lung
/ drug effects
Macrophages, Alveolar
/ drug effects
Male
Propofol
/ administration & dosage
Rats
Rats, Wistar
Thiopental
Tumor Necrosis Factor-alpha
/ biosynthesis
Vascular Cell Adhesion Molecule-1
/ biosynthesis
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 11 2021
30 11 2021
Historique:
received:
04
06
2021
accepted:
17
11
2021
entrez:
1
12
2021
pubmed:
2
12
2021
medline:
15
2
2022
Statut:
epublish
Résumé
Acute ischemic stroke is associated with pulmonary complications, and often dexmedetomidine and propofol are used to decrease cerebral metabolic rate. However, it is unknown the immunomodulatory actions of dexmedetomidine and propofol on brain and lungs during acute ischemic stroke. The effects of dexmedetomidine and propofol were compared on perilesional brain tissue and lung damage after acute ischemic stroke in rats. Further, the mean amount of both sedatives was directly evaluated on alveolar macrophages and lung endothelial cells primarily extracted 24-h after acute ischemic stroke. In twenty-five Wistar rats, ischemic stroke was induced and after 24-h treated with sodium thiopental (STROKE), dexmedetomidine and propofol. Dexmedetomidine, compared to STROKE, reduced diffuse alveolar damage score [median(interquartile range); 12(7.8-15.3) vs. 19.5(18-24), p = 0.007)], bronchoconstriction index [2.28(2.08-2.36) vs. 2.64(2.53-2.77), p = 0.006], and TNF-α expression (p = 0.0003), while propofol increased VCAM-1 expression compared to STROKE (p = 0.0004). In perilesional brain tissue, dexmedetomidine, compared to STROKE, decreased TNF-α (p = 0.010), while propofol increased VCAM-1 compared to STROKE (p = 0.024). In alveolar macrophages and endothelial cells, dexmedetomidine decreased IL-6 and IL-1β compared to STROKE (p = 0.002, and p = 0.040, respectively), and reduced IL-1β compared to propofol (p = 0.014). Dexmedetomidine, but not propofol, induced brain and lung protection in experimental acute ischemic stroke.
Identifiants
pubmed: 34848804
doi: 10.1038/s41598-021-02608-1
pii: 10.1038/s41598-021-02608-1
pmc: PMC8633001
doi:
Substances chimiques
Hypnotics and Sedatives
0
IL1B protein, rat
0
Il6 protein, rat
0
Interleukin-1beta
0
Interleukin-6
0
Tumor Necrosis Factor-alpha
0
Vascular Cell Adhesion Molecule-1
0
Dexmedetomidine
67VB76HONO
Thiopental
JI8Z5M7NA3
Propofol
YI7VU623SF
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
23133Informations de copyright
© 2021. The Author(s).
Références
Inflammation. 2014 Oct;37(5):1763-70
pubmed: 24803295
J Biochem Biophys Methods. 2007 Apr 10;70(3):481-6
pubmed: 17196660
PLoS One. 2018 Jul 5;13(7):e0200135
pubmed: 29975761
Clin Pharmacol. 2012;4:53-63
pubmed: 23204873
Respir Physiol Neurobiol. 2013 Feb 1;185(3):615-24
pubmed: 23164835
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Resuscitation. 2009 Oct;80(10):1204-10
pubmed: 19608326
PLoS Biol. 2020 Jul 14;18(7):e3000411
pubmed: 32663221
Minerva Anestesiol. 2020 Feb;86(2):181-195
pubmed: 31680494
Anesthesiology. 2001 May;94(5):851-5; discussion 6A
pubmed: 11388537
J Crit Care. 2020 Apr;56:281-287
pubmed: 32001426
Ann Fr Anesth Reanim. 2004 Aug;23(8):811-8
pubmed: 15345253
Anesth Analg. 2016 Apr;122(4):1015-23
pubmed: 26720616
J Anesth. 2005;19(1):40-4
pubmed: 15674515
J Cereb Blood Flow Metab. 2007 May;27(5):963-74
pubmed: 16985506
World J Crit Care Med. 2015 Aug 04;4(3):163-78
pubmed: 26261769
Cell Physiol Biochem. 2015;36(4):1644-58
pubmed: 26160269
Brain Res. 2013 Feb 4;1494:1-8
pubmed: 23219579
J Vis Exp. 2013 Oct 16;(80):e51079
pubmed: 24192721
Chest. 2016 Nov;150(5):1109-1117
pubmed: 27477213
Anesthesiology. 2008 Feb;108(2):225-32
pubmed: 18212567
J Cell Sci. 2008 Feb 15;121(Pt 4):504-13
pubmed: 18230652
Crit Care. 2018 Oct 5;22(1):249
pubmed: 30290827
Crit Care. 2011;15(3):168
pubmed: 21722336
Neurochem Res. 2011 Oct;36(10):1724-31
pubmed: 21556843
Cell Mol Neurobiol. 2016 Oct;36(7):1179-88
pubmed: 26683659
J Surg Res. 2011 May 15;167(2):e273-81
pubmed: 20452617
PLoS One. 2013 Dec 09;8(12):e82729
pubmed: 24349350
J Neuroinflammation. 2011 Dec 10;8:174
pubmed: 22152337
BMC Anesthesiol. 2017 Sep 20;17(1):130
pubmed: 28931374
Anesthesiology. 2004 Feb;100(2):359-63
pubmed: 14739811
Ann Indian Acad Neurol. 2013 Apr;16(2):194-202
pubmed: 23956563
Crit Care. 2016 Dec 7;20(1):391
pubmed: 27923376
Anesthesiology. 2013 Feb;118(2):395-408
pubmed: 23268840
Front Neurol. 2020 Sep 03;11:1001
pubmed: 33013661
Curr Neuropharmacol. 2005 Oct;3(4):317-23
pubmed: 18369397
Brain Res. 2005 Feb 21;1035(1):24-31
pubmed: 15713273
Pharmacol Rev. 1980 Dec;32(4):337-62
pubmed: 6267618
Cell Physiol Biochem. 2017;42(5):1907-1919
pubmed: 28873369
Int J Mol Med. 2014 Oct;34(4):1032-8
pubmed: 25069417
J Int Med Res. 2009 Mar-Apr;37(2):281-8
pubmed: 19383220
Prog Neurobiol. 2014 Apr;115:157-88
pubmed: 24361499
Acta Anaesthesiol Scand. 2002 Aug;46(7):831-5
pubmed: 12139539
Physiol Rev. 2018 Apr 1;98(2):813-880
pubmed: 29488822
Ann N Y Acad Sci. 2010 Oct;1207:32-40
pubmed: 20955423
Sci Rep. 2018 Jan 12;8(1):568
pubmed: 29330443
Exp Neurobiol. 2018 Aug;27(4):287-298
pubmed: 30181691
Cell Death Dis. 2020 Jun 2;11(6):415
pubmed: 32488063